Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain

Journal of Neuroscience

Volumn 30, Issue 44, 2010, Pages 14649-14656

  Jimenez Andrade, Juan M ^a   Bloom, Aaron P ^a   Stake, James I ^a   Mantyh, William G ^a   Taylor, Reid N ^a   Freeman, Katie T ^c   Ghilardi, Joseph R ^c   Kuskowski, Michael A ^c   Mantyh, Patrick W ^a,b,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; MESSENGER RNA; NERVE GROWTH FACTOR; TRKA ENZYME; TROPOMYOSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE PAIN; CANCER CELL; CANCER GROWTH; CANCER PAIN; CONTROLLED STUDY; MALE; MOUSE; NOCICEPTIVE RECEPTOR; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SENSORY NERVE; STROMA CELL;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOGS; MALE; MICE; MICE, NUDE; NOCICEPTORS; PAIN; PROSTATIC NEOPLASMS; SENSORY RECEPTOR CELLS;

EID: 78049509543     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3300-10.2010     Document Type: Article

References (53)

1. Ballantyne JC (2001) Pre-emptive analgesia: an unsolved problem. Curr Opin Anesthesiol 14:499-504.
2. Bamji SX, Majdan M, Pozniak CD, Belliveau DJ, Aloyz R, Kohn J, Causing CG, Miller FD (1998) The p75 neurotrophin receptor mediates neuronal apoptosis and is essential for naturally occurring sympathetic neuron death. J Cell Biol 140:911-923.
3. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D, Angeli A (2000) Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164:1248-1253.
4. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254-265.
5. Black JA, Nikolajsen L, Kroner K, Jensen TS, Waxman SG (2008) Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol 64:644-653.
6. Boyle P, Levin B, eds (2008) World cancer report 2008. Lyon: International Agency for Research on Cancer.
7. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578-583.
8. Ceyhan GO, Bergmann F, Kadihasanoglu M, Altintas B, Demir IE, Hinz U, Müller MW, Giese T, Büchler MW, Giese NA, Friess H (2009) Pancreatic neuropathy and neuropathic pain-a comprehensive pathomorphological study of 546 cases. Gastroenterology 136:177-186 e1.
9. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s-6249s.
10. Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736-1740.
11. de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, Sturkenboom MC (2007) The incidence of complex regional pain syndrome: a population-based study. Pain 129:12-20.
12. Denny JB (2006) Molecular mechanisms, biological actions, and neuropharmacology of the growth-associated protein GAP-43. Curr Neuropharmacol 4:293-304.
13. DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869-876.
14. di Mola FF, Friess H, Zhu ZW, Koliopanos A, Bley T, Di Sebastiano P, Innocenti P, Zimmermann A, Büchler MW (2000) Nerve growth factor and Trk high affinity receptor (TrkA) gene expression in inflammatory bowel disease. Gut 46:670-679.
15. Dy SM, Asch SM, Naeim A, Sanati H, Walling A, Lorenz KA (2008) Evidence-based standards for cancer pain management. J Clin Oncol 26:3879-3885.
16. Fukumura D, Jain RK (2007) Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 74:72-84.
17. Gallo G, Lefcort FB, Letourneau PC (1997) The trkA receptor mediates growth cone turning toward a localized source of nerve growth factor. J Neurosci 17:5445-5454.
18. Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, Rosol TJ, Boustany L, Shelton DL, Mantyh PW (2005) A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 65:9426-9435.
19. Hongo JS, Laramee GR, Urfer R, Shelton DL, Restivo T, Sadick M, Galloway A, Chu H, Winslow JW (2000) Antibody binding regions on human nerve growth factor identified by homolog-and alanine-scanning mutagenesis. Hybridoma 19:215-227.
20. Hwang SS, Chang VT, Kasimis B (2003) Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 101:55-64.
21. Inman VT, Saunders JB (1944) Referred pain from skeletal structures. J Nerve Ment Dis 99:660-667.
22. Ivanusic JJ, Mahns DA, Sahai V, Rowe MJ (2006) Absence of large-diameter sensory fibres in a nerve to the cat humerus. J Anat 208:251-255.
23. Jänig W, Baron R (2003) Complex regional pain syndrome: mystery explained? Lancet Neurol 2:687-697.
24. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
25. Jimenez-Andrade JM, Mantyh WG, Bloom AP, Xu H, Ferng AS, Dussor G, Vanderah TW, Mantyh PW (2010) A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: therapeutic opportunity for treating skeletal pain. Bone 46:306-313.
26. Key ME (1983) Macrophages in cancer metastases and their relevance to metastatic growth. Cancer Metastasis Rev 2:75-88.
27. Kivelä R, Havas E, Vihko V (2007) Localisation of lymphatic vessels and vascular endothelial growth factors-C and-D in human and mouse skeletal muscle with immunohistochemistry. Histochem Cell Biol 127:31-40.
28. Lindqvist A, Rivero-Melian C, Turan I, Fried K (2000) Neuropeptide- and tyrosine hydroxylase-immunoreactive nerve fibers in painful Morton's neuromas. Muscle Nerve 23:1214-1218.
29. Lindsay TH, Jonas BM, Sevcik MA, Kubota K, Halvorson KG, Ghilardi JR, Kuskowski MA, Stelow EB, Mukherjee P, Gendler SJ, Wong GY, Mantyh PW (2005) Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. Pain 119:233-246.
30. Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O'Leary P, Mantyh PW (2002) Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 113:155-166.
31. Mahns DA, Ivanusic JJ, Sahai V, Rowe MJ (2006) An intact peripheral nerve preparation for monitoring the activity of single, periosteal afferent nerve fibres. J Neurosci Methods 156:140-144.
32. Martin CD, Jimenez-Andrade JM, Ghilardi JR, Mantyh PW (2007) Organization of a unique net-like meshwork of CGRP+ sensory fibers in the mouse periosteum: implications for the generation and maintenance of bone fracture pain. Neurosci Lett 427:148-152.
33. Mercadante S, Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24:425-432. (Pubitemid 29121682)
34. Mercadante S, Villari P, Ferrera P, Casuccio A (2004) Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage 28:505-510.
35. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S (2001) Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93:247-257.
36. Nassenstein C, Schulte-Herbrüggen O, Renz H, Braun A (2006) Nerve growth factor: the central hub in the development of allergic asthma? Eur J Pharmacol 533:195-206.
37. Normann SJ (1985) Macrophage infiltration and tumor progression. Cancer Metastasis Rev 4:277-291.
38. Odaka C, Morisada T, Oike Y, Suda T (2006) Distribution of lymphatic vessels in mouse thymus: immunofluorescence analysis. Cell Tissue Res 325:13-22.
39. Peters CM, Ghilardi JR, Keyser CP, Kubota K, Lindsay TH, Luger NM, Mach DB, Schwei MJ, Sevcik MA, Mantyh PW (2005) Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp Neurol 193:85-100.
40. Pezet S, McMahon SB (2006) Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 29:507-538.
41. Pogatzki-Zahn EM, Zahn PK (2006) From preemptive to preventive analgesia. Curr Opin Anaesthesiol 19:551-555.
42. Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41:273-281.
43. Rajarubendra N, Bolton D, Lawrentschuk N (2010) Diagnosis of bone metastases in urological malignancies - an update. Urology. Advance online publication. Retrieved May 27, 2010. doi:10.1016/j.urology.2009.12.050.
44. Rigaud J, Tiguert R, Le Normand L, Karam G, Glemain P, Buzelin JM, Bouchot O (2002) Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 168:1423-1426.
45. Sabino MA, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, Peters CM, Rogers SD, Schwei MJ, de Felipe C, Mantyh PW (2002) Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 62:7343-7349.
46. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW (1999) Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19:10886-10897.
47. Sevcik MA, Luger NM, Mach DB, Sabino MA, Peters CM, Ghilardi JR, Schwei MJ, Röhrich H, De Felipe C, Kuskowski MA, Mantyh PW (2004) Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 111:169-180.
48. Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, Boustany L, Shelton DL, Mantyh PW (2005) Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115:128-141.
49. Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A (2005) Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 116:8-16.
50. Tang P, Hicks DG (2010) The histopathology of skeletal metastases. In: Bone cancer: progression and therapeutic approaches (Heymann D, ed), pp 243-250. New York: Elsevier.
51. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579-584.
52. Woolf CJ, Chong MS (1993) Preemptive analgesia - treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 77:362-379.
53. Yen LD, Bennett GJ, Ribeiro-da-Silva A (2006) Sympathetic sprouting and changes in nociceptive sensory innervation in the glabrous skin of the rat hindpaw following partial peripheral nerve injury. J Comp Neurol 495:679-690.